This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

9 Meters Biopharma Croissance future

Future contrôle des critères 2/6

9 Meters Biopharma devrait augmenter ses bénéfices et son chiffre d'affaires de 41.4% et de 56.6% par an respectivement. Le BPA devrait croître de de 39.9% par an. Le rendement des capitaux propres devrait être -185.6% dans 3 ans.

Informations clés

41.4%

Taux de croissance des bénéfices

39.9%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	23.7%
Taux de croissance des recettes	56.6%
Rendement futur des capitaux propres	-185.6%
Couverture par les analystes	Low
Dernière mise à jour	30 May 2023

Mises à jour récentes de la croissance future

Recent updates

9 Meters Biopharma to execute 1-for-20 reverse stock split

Oct 17

9 Meters Biopharma GAAP EPS of -$0.04 in-line

Aug 15

9 meters launches Phase 2 VIBRANT study of vurolenatide for short bowel syndrome

Jun 14

9 Meters drug effective in treating rare COVID-19 complication in children

May 26

9 Meters Bio gains 5% on Adage Capital stake disclosure

Dec 29

9 Meters Biopharma slumps, continues evaluation of Larazotide for COVID-19 respiratory complications

Dec 21

9 Meters Bio launches equity offering

Dec 11

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:NMTR - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2025	N/A	-43	N/A	N/A	2
12/31/2024	N/A	-41	N/A	N/A	3
12/31/2023	3	-43	N/A	N/A	4
3/31/2023	N/A	-46	-37	-37	N/A
12/31/2022	N/A	-44	-37	-37	N/A
9/30/2022	N/A	-41	-35	-35	N/A
6/30/2022	N/A	-46	-36	-34	N/A
3/31/2022	N/A	-43	-36	-33	N/A
12/31/2021	N/A	-37	-32	-29	N/A
9/30/2021	N/A	-32	-30	-28	N/A
6/30/2021	N/A	-27	-24	-24	N/A
3/31/2021	N/A	-63	-26	-23	N/A
12/31/2020	N/A	-61	-23	-19	N/A
9/30/2020	N/A	-65	-19	-16	N/A
6/30/2020	N/A	-66	-19	-16	N/A
3/31/2020	N/A	-26	-16	-16	N/A
12/31/2019	N/A	-27	-18	-18	N/A
9/30/2019	N/A	-22	-17	-17	N/A
6/30/2019	N/A	-14	-17	-17	N/A
3/31/2019	N/A	-14	-12	-12	N/A
12/31/2018	N/A	-24	-15	-15	N/A
9/30/2018	N/A	-22	-15	-15	N/A
6/30/2018	N/A	-24	-12	-12	N/A
3/31/2018	N/A	-23	-11	-11	N/A
12/31/2017	N/A	-12	-5	-5	N/A
9/30/2017	N/A	-11	-4	-4	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: NMTR devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: NMTR devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: NMTR devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de NMTR ( 56.6% par an) devrait croître plus rapidement que le marché US ( 8.9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de NMTR ( 56.6% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: NMTR devrait être non rentable dans 3 ans.

This company listing is no longer active

9 Meters Biopharma Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 43% to US$10.25

Consensus EPS estimates fall by 43%

Price target decreased by 32% to US$22.68

Price target increased by 18% to US$39.20

Price target decreased by 15% to US$33.12

Price target decreased to US$57.00

Recent updates

9 Meters Biopharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Rule

9 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO

9 Meters Biopharma, Inc. Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

Price target decreased by 43% to US$10.25

Consensus EPS estimates fall by 43%

Price target decreased by 32% to US$22.68

Price target increased by 18% to US$39.20

Price target decreased by 15% to US$33.12

9 Meters Biopharma, Inc. Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome

High number of new and inexperienced directors

Price target decreased to US$57.00

9 Meters Biopharma to execute 1-for-20 reverse stock split

Price target increased to US$3.40

9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma GAAP EPS of -$0.04 in-line

9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma, Inc. announced that it expects to receive $70 million in funding

Price target decreased to US$3.33

Independent Chairman recently bought US$50k worth of stock

9 Meters Biopharma, Inc., Annual General Meeting, Jun 22, 2022

High number of new and inexperienced directors

President recently bought US$56k worth of stock

9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease

Price target decreased to US$4.33

President recently bought US$53k worth of stock

President recently bought US$53k worth of stock

Independent Chairman recently bought US$100k worth of stock

Director Sandeep Laumas has left the company

9 Meters Biopharma, Inc. Announces Initiation of Phase 2 Vibrant Study of Vurolenatide for Short Bowel Syndrome

9 meters launches Phase 2 VIBRANT study of vurolenatide for short bowel syndrome

9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children Resulting from Covid-19 Infection

9 Meters drug effective in treating rare COVID-19 complication in children

9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome

Forecast to breakeven in 2024

9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update

9 Meters Biopharma Inc Appoints Michael Rice as Board of Director

9 Meters Biopharma, Inc. Announces the Resignation of Nissim Darvish as Director

Independent Director has left the company

New 90-day high: US$1.50

New 90-day high: US$1.37

9 Meters Bio gains 5% on Adage Capital stake disclosure

9 Meters Biopharma slumps, continues evaluation of Larazotide for COVID-19 respiratory complications

9 Meters Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $30.000001 million.

9 Meters Bio launches equity offering

9 Meters Biopharma Announces Positive Preclinical Data for NM-102, a Gut Microbiome Modulator in an Immune Checkpoint Inhibitor Failure Model

New 90-day high: US$0.89

New 90-day high: US$0.85

Independent Chairman recently bought US$96k worth of stock

Independent Chairman recently bought US$56k worth of stock

New 90-day low - US$0.47

Innovate Biopharmaceuticals, Inc. (NasdaqCM:INNT) completed the acquisition of RDD Pharma, Ltd. from OrbiMed Israel Partners managed by OrbiMed Advisors, L.L.C. and others.

9 Meters Biopharma, Inc.(NasdaqCM:NMTR) dropped from Russell Microcap Index

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance